First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

Conclusion: 89Zr-IAB22M2C imaging is safe and has favorable kinetics for early imaging. Biodistribution suggests successful targeting of CD8+ T-cell–rich tissues. The observed targeting of tumor lesions suggests this may be informative for CD8+ T-cell accumulation within tumors. Further evaluation is under way.

Source: Journal of Nuclear Medicine - March 31, 2020 Category: Nuclear Medicine Authors: Pandit-Taskar, N., Postow, M. A., Hellmann, M. D., Harding, J. J., Barker, C. A., ODonoghue, J. A., Ziolkowska, M., Ruan, S., Lyashchenko, S. K., Tsai, F., Farwell, M., Mitchell, T. C., Korn, R., Le, W., Lewis, J. S., Weber, W. A., Behera, D., Wilson, I., Tags: Translational Source Type: research